Predicting pharmacokinetic profile of therapeutic antibodies after iv injection from only the data after sc injection in cynomolgus monkey

References

• Bauer RJ, Dedrick RL, White ML, et al. (1999). Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 27:397–420
   PubMedGoogle Scholar
• Baxter LT, Zhu H, Mackensen DG, Jain RK. (1994). Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 54:1517–28
   PubMed Web of Science ®Google Scholar
• Benincosa LJ, Chow FS, Tobia LP, et al. (2000). Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys. J Pharmacol Exp Ther 292:810–16
   PubMed Web of Science ®Google Scholar
• Borrok MJ, Wu Y, Beyaz N, et al. (2015). pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling. J Biol Chem 290:4282–90
   PubMed Web of Science ®Google Scholar
• Chow FS, Benincosa LJ, Sheth SB, et al. (2002). Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans. Clin Pharmacol Ther 71:235–45
   PubMed Web of Science ®Google Scholar
• Covell DG, Barbet J, Holton OD, et al. (1986). Pharmacokinetics of monoclonal immunoglobulin G1, F(ab′)2, and Fab′ in mice. Cancer Res 46:3969–78
   PubMed Web of Science ®Google Scholar
• Dall'acqua WF, Kiener PA, Wu H. (2006). Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 281:23514–24
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Witcher DR, Lu J, Wroblewski VJ. (2012). Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys. MAbs 4:267–73
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Witcher DR, Tang Y, et al. (2007). Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. J Biol Chem 282:1709–17
   PubMed Web of Science ®Google Scholar
• Davis CB, Hepburn TW, Urbanski JJ, et al. (1995). Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19. Drug Metab Dispos 23:1028–36
   PubMed Web of Science ®Google Scholar
• Deng R, Iyer S, Theil FP, et al. (2011). Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs 3:61–6
   PubMed Web of Science ®Google Scholar
• Dong JQ, Salinger DH, Endres CJ, et al. (2011). Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet 50:131–42
   PubMed Web of Science ®Google Scholar
• Dowall S, Taylor I, Yeates P, et al. (2013). Catheterized guinea pigs infected with Ebola Zaire virus allows safer sequential sampling to determine the pharmacokinetic profile of a phosphatidylserine-targeting monoclonal antibody. Antiviral Res 97:108–11
   PubMed Web of Science ®Google Scholar
• Ecker DM, Jones SD, Levine HL. (2015). The therapeutic monoclonal antibody market. MAbs 7:9–14
   PubMed Web of Science ®Google Scholar
• Elvin JG, Couston RG, Van Der Walle CF. (2013). Therapeutic antibodies: market considerations, disease targets and bioprocessing. Int J Pharm 440:83–98
   PubMed Web of Science ®Google Scholar
• Finch DK, Sleeman MA, Moisan J, et al. (2011). Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics. J Mol Biol 411:791–807
   PubMed Web of Science ®Google Scholar
• Garg A, Balthasar JP. (2007). Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn 34:687–709
   PubMed Web of Science ®Google Scholar
• Halpern WG, Lappin P, Zanardi T, et al. (2006). Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci 91:586–99
   PubMed Web of Science ®Google Scholar
• Han C, Gunn GR, Marini JC, et al. (2015). Pharmacokinetics and immunogenicity investigation of a human anti-interleukin-17 monoclonal antibody in non-naive cynomolgus monkeys. Drug Metab Dispos 43:762–70
   PubMed Web of Science ®Google Scholar
• Hansen L, Petersen LC, Lauritzen B, et al. (2014). Target-mediated clearance and bio-distribution of a monoclonal antibody against the Kunitz-type protease inhibitor 2 domain of tissue factor pathway inhibitor. Thromb Res 133:464–71
   PubMed Web of Science ®Google Scholar
• Haraya K, Tachibana T, Nanami M, Ishigai M. (2014). Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody. Xenobiotica 44:1127–34
   PubMed Web of Science ®Google Scholar
• Hotzel I, Theil FP, Bernstein LJ, et al. (2012). A strategy for risk mitigation of antibodies with fast clearance. MAbs 4:753–60
   PubMed Web of Science ®Google Scholar
• Igawa T, Ishii S, Tachibana T, et al. (2010a). Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol 28:1203–7
   PubMed Web of Science ®Google Scholar
• Igawa T, Tsunoda H, Tachibana T, et al. (2010b). Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel 23:385–92
   PubMed Web of Science ®Google Scholar
• Israel EJ, Wilsker DF, Hayes KC, et al. (1996). Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn. Immunology 89:573–8
   PubMed Web of Science ®Google Scholar
• Kakkar T, Ma M, Zhuang Y, et al. (2007). Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, AMG 102, in cynomolgus monkeys. Pharm Res 24:1910–18
   PubMed Web of Science ®Google Scholar
• Kelley SK, Gelzleichter T, Xie D, et al. (2006). Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Br J Pharmacol 148:1116–23
   PubMed Web of Science ®Google Scholar
• Kienast Y, Klein C, Scheuer W, et al. (2013). Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin Cancer Res 19:6730–40
   PubMed Web of Science ®Google Scholar
• Ko SY, Pegu A, Rudicell RS, et al. (2014). Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514:642–5
   PubMed Web of Science ®Google Scholar
• Kock K, Pan WJ, Gow JM, et al. (2015). Preclinical development of AMG 139, a human antibody specifically targeting IL-23. Br J Pharmacol 172:159–72
   PubMed Web of Science ®Google Scholar
• Lacy SE, Wu C, Ambrosi DJ, et al. (2015). Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig™) molecule that specifically and potently neutralizes both IL-1alpha and IL-1beta. MAbs 7:605–19
   PubMed Web of Science ®Google Scholar
• Leabman MK, Meng YG, Kelley RF, et al. (2013). Effects of altered FcgammaR binding on antibody pharmacokinetics in cynomolgus monkeys. MAbs 5:896–903
   PubMed Web of Science ®Google Scholar
• Li H, Kock K, Wisler JA, et al. (2015). Prediction of clinical pharmacokinetics of AMG 181, a human anti-alpha 4 beta 7 monoclonal antibody for treating inflammatory bowel diseases. Pharmacol Res Perspect 3:e00098
   PubMed Web of Science ®Google Scholar
• Lin YS, Nguyen C, Mendoza JL, et al. (1999). Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288:371–8
   PubMed Web of Science ®Google Scholar
• Mahmood I. (2009). Pharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimation. J Pharm Sci 98:3850–61
   PubMed Web of Science ®Google Scholar
• Mimoto F, Igawa T, Kuramochi T, et al. (2013). Novel asymmetrically engineered antibody Fc variant with superior FcgammaR binding affinity and specificity compared with afucosylated Fc variant. MAbs 5:229–36
   PubMed Web of Science ®Google Scholar
• Mizuta E, Tsubotani A. (1985). Preparation of mean drug concentration–time curves in plasma. A study on the frequency distribution of pharmacokinetic parameters. Chem Pharm Bull (Tokyo) 33:1620–32
   PubMed Web of Science ®Google Scholar
• Monnet C, Jorieux S, Souyris N, et al. (2014). Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody. MAbs 6:422–36
   PubMed Web of Science ®Google Scholar
• Mortensen DL, Prabhu S, Stefanich EG, et al. (2012). Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies. MAbs 4:724–31
   PubMed Web of Science ®Google Scholar
• Muto A, Yoshihashi K, Takeda M, et al. (2014). Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood 124:3165–71
   PubMed Web of Science ®Google Scholar
• Nesspor TC, Scallon B. (2014). Chimeric antibodies with extended half-life in ferrets. Influenza Other Respir Viruses 8:596–604
   PubMed Web of Science ®Google Scholar
• Neuber T, Frese K, Jaehrling J, et al. (2014). Characterization and screening of IgG binding to the neonatal Fc receptor. MAbs 6:928–42
   PubMed Web of Science ®Google Scholar
• Nnane IP, Xu Z, Zhou H, Davis HM. (2015). Non-Clinical pharmacokinetics, prediction of human pharmacokinetics and first-in-human dose selection for CNTO 5825, an anti-interleukin-13 monoclonal antibody. Basic Clin Pharmacol Toxicol 117:219–25
   PubMed Web of Science ®Google Scholar
• PMDA. (2008). Adalimumab (Humira). Available at: http://www.info.pmda.go.jp/shinyaku/P200800019/index.html
   Google Scholar
• PMDA. (2009). Omalizumab (Xolair). Available at: http://www.info.pmda.go.jp/shinyaku/P200900001/index.html
   Google Scholar
• PMDA. (2011). Golimumab (Simponi). Available at: http://www.info.pmda.go.jp/shinyaku/P201100114/index.html
   Google Scholar
• Robbie GJ, Criste R, Dall'Acqua WF, et al. (2013). A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother 57:6147–53
   PubMed Web of Science ®Google Scholar
• Ryan PC, Sleeman MA, Rebelatto M, et al. (2014). Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: relevance for human safety. Toxicol Appl Pharmacol 279:230–9
   PubMed Web of Science ®Google Scholar
• Spiess C, Bevers J, 3rd, Jackman J, et al. (2013). Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines. J Biol Chem 288:26583–93
   PubMed Web of Science ®Google Scholar
• Stephens S, Emtage S, Vetterlein O, et al. (1995). Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology 85:668–74
   PubMed Web of Science ®Google Scholar
• Tam SH, Mccarthy SG, Brosnan K, et al. (2013). Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities. MAbs 5:397–405
   PubMed Web of Science ®Google Scholar
• Vugmeyster Y, Szklut P, Wensel D, et al. (2011). Complex pharmacokinetics of a humanized antibody against human amyloid beta peptide, anti-abeta Ab2, in nonclinical species. Pharm Res 28:1696–706
   PubMed Web of Science ®Google Scholar
• Wang W, Wang X, Doddareddy R, et al. (2014). Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys. AAPS J 16:129–39
   PubMed Web of Science ®Google Scholar
• Xiao JJ, Krzyzanski W, Wang YM, et al. (2010). Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPS J 12:646–57
   PubMed Web of Science ®Google Scholar
• Xu Z, Bouman-Thio E, Comisar C, et al. (2011). Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol 72:270–81
   PubMed Web of Science ®Google Scholar
• Yu M, Brown D, Reed C, et al. (2012). Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans. MAbs 4:475–87
   PubMed Web of Science ®Google Scholar
• Zalevsky J, Chamberlain AK, Horton HM, et al. (2010). Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 28:157–9
   PubMed Web of Science ®Google Scholar
• Zhou H, Jang H, Fleischmann RM, et al. (2007). Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol 47:383–96
   PubMed Web of Science ®Google Scholar
• Zia-Amirhosseini P, Minthorn E, Benincosa LJ, et al. (1999). Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. J Pharmacol Exp Ther 291:1060–7
   PubMed Web of Science ®Google Scholar
• Zorbas M, Hurst S, Shelton D, et al. (2011). A multiple-dose toxicity study of tanezumab in cynomolgus monkeys. Regul Toxicol Pharmacol 59:334–42
   PubMed Web of Science ®Google Scholar
• Zornoza T, Cano-Cebrian MJ, Hipolito L, et al. (2006). Evidence of a flip-flop phenomenon in acamprosate pharmacokinetics: an in vivo study in rats. Biopharm Drug Dispos 27:305–11
   PubMed Web of Science ®Google Scholar